Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 96Carcinoma, Non-Small-Cell Lung 85Prostatic Neoplasms 75Multiple Myeloma 74Neoplasms 50Leukemia, Myeloid, Acute 44Lymphoma 43Melanoma 42Neoplasm Metastasis 39Ovarian Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Lymphoma, Non-Hodgkin 34Lung Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 32Hematologic Neoplasms 29Colorectal Neoplasms 29Triple Negative Breast Neoplasms 27Hodgkin Disease 24Pancreatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 21Fallopian Tube Neoplasms 21Carcinoma, Renal Cell 21Sarcoma 20Lymphoma, Follicular 20Urinary Bladder Neoplasms 18Recurrence 18Lymphoma, Mantle-Cell 18Head and Neck Neoplasms 18Brain Neoplasms 18

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anal Canal Carcinoma × 90 days × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡